BioCentury | Dec 7, 2019
Product Development

U.S. biosimilars glass--half full or half empty?

...prior. The exception is Retacrit epoetin alfa-epbx, which is priced below the 2005 level of Epogen...
...Amgen is on both sides of the biosimilar equation, fighting off competition for Neulasta and Epogen...
BioCentury | Jul 10, 2019
Politics & Policy

CMS’s new CKD payment models could be mixed bag for drug companies

...in these patients are erythropoiesis stimulating agents (ESAs). In the U.S., Amgen Inc. (NASDAQ:AMGN) markets Epogen...
...for publication to questions on the potential ramifications of the new payment models on its Epogen...
BioCentury | Nov 16, 2018
Clinical News

Pfizer launches U.S.’s first biosimilar epoetin

...a 33.5% discount to the lowest priced reference product. Amgen Inc. (NASDAQ:AMGN) markets reference drug Epogen...
...1,000 units/mL. That WAC is 57.1% below Procrit's WAC of $25.72 and 33.5% below the Epogen's...
BioCentury | Nov 15, 2018
Company News

Pfizer launches U.S.’s first biosimilar epoetin

...a 33.5% discount to the lowest priced reference product. Amgen Inc. (NASDAQ:AMGN) markets reference drug Epogen...
...1,000 units/mL. That WAC is 57.1% below Procrit's WAC of $25.72 and 33.5% below the Epogen's...
BioCentury | Jul 27, 2018
Regulation

Biosimilar barriers

...biosimilar status Johnson & Johnson (NYSE:JNJ) Remicade infliximab $4,525.0 8/24/98 2018 Marketed Amgen Inc. (NASDAQ:AMGN) Epogen...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...Inc. (NYSE:PFE) / Stada Arzneimittel AG (Xetra:SAZ) FDA approves Retacrit epoetin alfa-epbx, a biosimilar of Epogen...
BioCentury | May 18, 2018
Clinical News

FDA approves Pfizer's Retacrit, first epoetin alfa biosimilar in U.S.

...FDA approved Retacrit epoetin alfa-epbx from Pfizer Inc. (NYSE:PFE), a biosimilar of anemia drugs Epogen from...
...cost (WAC) of Epogen and Procrit. The WAC for 2 ml of 10,000 units/ml of Epogen...
...Europe has reached 51%. In 2017, Amgen reported annual U.S. revenues of $1.1 billion for Epogen...
BioCentury | May 15, 2018
Company News

FDA approves Pfizer's Retacrit, first epoetin alfa biosimilar in U.S.

...FDA approved Retacrit epoetin alfa-epbx from Pfizer Inc. (NYSE:PFE), a biosimilar of anemia drugs Epogen from...
...cost (WAC) of Epogen and Procrit. The WAC for 2 ml of 10,000 units/ml of Epogen...
...Europe has reached 51%. In 2017, Amgen reported annual U.S. revenues of $1.1 billion for Epogen...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Japan Tobacco Inc. (Tokyo:2914) Stribild elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate $1,914.0 $831.0 $1,108.0 -42% Amgen Inc. (NASDAQ:AMGN) Epogen...
BioCentury | Nov 30, 2017
Company News

Amgen buys out Kyowa JV

...up to about $30 million from Amgen in sales milestones. The JV developed marketed drugs Epogen...
...NASDAQ:AMGN), Thousand Oaks, Calif. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Business: Pharmaceuticals Jennie Walters Aranesp brodalumab darbepoetin alfa Epogen filgrastim Neulasta Neupogen Nplate romiplostim Amgen...
Items per page:
1 - 10 of 645